Insulin-like Growth Factor 1 Receptor Expression Correlates

with Programmed Death Ligand 1 Expression and Poor

Survival in Non-small Cell Lung Cancer

- 5 Hiroaki Nagamine^{1,3}¶, Masakazu Yashiro²*¶, Megumi Mizutani³, Akira Sugimoto³,
- 6 Yoshiya Matsumoto³, Yoko Tani⁴, Kenji Sawa⁴, Hiroyasu Kaneda⁴, Kazuhiro Yamada³,
- 7 Tetsuya Watanabe³, Kazuhisa Asai³, Satoshi Suzuki^{5&}, Tomoya Kawaguchi^{3,4}
- 9 1 Department of Respiratory Medicine, Osaka City University, Graduate School of
- 10 Medicine, Osaka, Japan

1

2

3

4

8

- 11 2 Molecular Oncology and Therapeutics, Osaka Metropolitan University, Graduate
- 12 School of Medicine, Osaka, Japan
- 13 Department of Respiratory Medicine, Osaka Metropolitan University, Graduate
- 14 School of Medicine, Osaka, Japan
- 15 4 Department of Clinical Oncology, Osaka Metropolitan University, Graduate School
- of Medicine, Osaka, Japan
- 17 5 Department of Thoracic Surgery, Osaka Metropolitan University, Graduate School
- of Medicine, Osaka, Japan

19	
20	*Corresponding Author:
21	Masakazu Yashiro
22	ORCID: Masakazu Yashiro (https://orcid.org/0000-0001-5743-7228)
23	Email: <u>i21496f@omu.ac.jp</u> (MY)
24	
25	These authors contributed equally to this work.
26	&These authors also contributed equally to this work.
27	
28	Short title: IGF1R is associated with PD-L1 expression and poor survival in
29	NSCLC
30	
31	Keywords: IGF1R, lung cancer, NSCLC, OS, PD-L1, RFS

Abstract

32

33 The insulin-like growth factor 1 receptor (IGF1R) has been associated with growth and 34 metastasis in various cancers. However, its role in postoperative recurrence and 35 prognosis in lung cancer lacks clear consensus. Therefore, this study aimed to investigate the potential relationship between IGF1R and postoperative recurrence as 36 well as long-term survival in a large cohort. Additionally, we assessed the relationship 37 between IGF1R and programmed death ligand 1 (PD-L1) expression. Our study 38 39 encompassed 782 patients with non-small cell lung cancer (NSCLC). Immunostaining 40 of surgical specimens was performed to evaluate IGF1R and PD-L1 expression. Among the patients, 279 (35.8%) showed positive IGF1R expression, with significantly worse 41 42 relapse-free survival (RFS) and overall survival (OS). Notably, no significant 43 differences in RFS and OS were observed between IGF1R-positive and -negative groups in stages 2 and 3. However, in the early stages (0-1), the positive group 44 45 displayed significantly worse RFS and OS. In addition, PD-L1 expression was detected in 100 (12.8%) patients, with a significant predominance in the IGF1R-positive. IGF1R 46 47 may serve as a prognostic indicator and a guide for perioperative treatment strategies in 48 early-stage lung cancer. In conclusion, our findings underscore an association between 49 IGF1R expression and poor survival and PD-L1 expression in NSCLC.

Introduction

50

51

52

53

54

55

56

57

58

59

60

61

62

64

65

67

The insulin-like growth factor 1 receptor (IGF1R) is expressed in various cancers [1-3] and is associated with cancer growth [4], metastasis [5, 6], and malignancy [7, 8]. In lung cancer, particularly non-small cell lung cancer (NSCLC), IGF1R expression is associated with carcinogenesis and proliferation [9, 10]. Nevertheless, the association between IGF1R expression and postoperative prognosis as well as recurrence in lung cancer has been inconsistent [11-14], lacking a definitive consensus. In recent years, the expression of programmed death ligand 1 (PD-L1) has attracted attention as a predictor of immune checkpoint inhibitor (ICI) efficacy in the treatment of lung cancer [15]. Although the expression of IGF1R and PD-L1 has been implicated in head and neck squamous cell carcinoma [16], their role in lung cancer remains unknown. The development of lung cancers, particularly squamous cell 63 carcinoma (SCC), has been associated with smoking [17]. Moreover, smoking is known to be involved in tumor-induced IGF1R expression [10]. However, it remains unclear whether IGF1R expression is associated with smoking and PD-L1 expression in actual 66 clinical practice and whether it is involved in postoperative recurrence and survival in lung cancer. Therefore, this study aimed to investigate the potential associations

68 between IGF1R expression, PD-L1 expression, smoking history, postoperative 69 recurrence, and survival in lung cancer. To our knowledge, this is the first study to 70 comprehensively evaluate the relationship between IGF1R and these critical factors 71 using long-term observations on a large scale. We anticipate that our findings will 72 contribute to the ongoing efforts to optimize lung cancer management, leading to more 73 effective and personalized therapeutic interventions in the realm of precision medicine.

6/26

Materials and methods

Patient and data collection

74

75

76 A total of 782 patients with NSCLC who underwent surgery at the Osaka 77 Metropolitan University Hospital between January 2010 and December 2019 were included in this study. Cancer stage for all patients was assessed according to the Union 78 79 for International Cancer Control, 8th edition. Relapse-free survival (RFS) was calculated from the date of surgery to the date of first recurrence or death from any 80 81 cause. Overall survival (OS) was calculated from the date of surgery to the date of death 82 from any cause. Our observations were conducted retrospectively, with August 31, 2023, as the data cutoff date, spanning a maximum of 10 years. At the cut-off date or 10 83 years after the start of observation, cases with no events were terminated from 84 85 observation. Between September 1, 2023, and October 31, 2023, we accessed medical records for the collection of information, including personally identifiable details, 86 87 related to registered patients. This study was approved by the Osaka City university Ethics Committee (reference number 2019-006). Informed consent was obtained from 88 89 each patient. This study has been conducted according to the principles of the 90 declaration of Helsinki.

Immunohistochemistry

91

7/26

Immunohistochemical staining was performed on paraffin-embedded sections of primary surgically resected specimens obtained from patients with NSCLC. Slides were deparaffinized using xylene and rehydrated with gradually decreasing concentrations of ethyl alcohol. The slides were then incubated with methanol containing 3% hydrogen peroxide at room temperature for 15 min to eliminate endogenous peroxidase activity. Subsequently, the slides were heated in an autoclave at 105°C for 10 min in Target Retrieval Solution (Dako, Santa Clara, CA, USA). Following this, the slides were blocked with 10% normal mouse serum for 10 min at room temperature and incubated overnight at 4°C with the anti-IGF1R antibody (NB110-87052, 1:200; Novus Biologicals LLC, Centennial, CO, USA). Subsequently, the samples were incubated with a biotinylated secondary antibody for 10 min at room temperature, followed by treatment with streptavidin-peroxidase reagent for 5 min at room temperature, incubation in diaminobenzidine for 2 min at room temperature, and counterstaining with 100% Mayer's hematoxylin for 40 s at room temperature. For PD-L1 staining, sections were blocked with 10% normal rabbit serum, and an anti-PD-L1 antibody (ab205921, 1:150, Abcam, Cambridge, UK) was used as the primary antibody, followed by reaction with diaminobenzidine for 7 min.

Statistical analysis

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

111

112

113

114

115

116

117

118

119

120

121

122

123

The χ^2 test was employed to evaluate the significance of differences in patient characteristics between the IGF1R-positive and IGF1R-negative groups. Multiple logistic regression analysis was utilized to analyze the relationship between IGF1R and PD-L1 expression, incorporating factors age, sex, smoking history, Eastern Cooperative Oncology Group Performance Status (ECOG PS), histology, pStage, pleural invasion, lymphatic invasion, and vascular invasion. The Mann–Whitney U test was applied to evaluate differences in smoking index or maximum tumor diameter between the IGF1Rpositive and negative groups. Survival curves were generated using Kaplan-Meier method, and the log-rank test was used to compare cumulative survival durations in the patient groups. In addition, the Cox proportional hazards model was used to compute univariable and multivariable hazard ratios for the study parameters. Analyses were performed using EZR in R Commander version 1.54 (Saitama Medical Center, Jichi Medical University, Saitama, Japan). In all tests, p < 0.05 was considered to indicate statistical significance.

Results

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Patient characteristics and the association of IGF1R expression with

smoking history and tumor size

A total of 782 patients were included in this study. Both IGF1R and PD-L1 were predominantly stained in the cytoplasm (Fig. 1A and 1B). IGF1R was identified as positive in 279 patients (35.8%). The median age of the participants was 70.0 years (range=33-91), with 497 (63.6%) patients being male. Five hundred twenty-one patients had adenocarcinoma, 217 had SCC, 14 had adenosquamous cell carcinoma, 11 had large cell carcinoma, nine had pleomorphic carcinoma, three had large cell neuroendocrine carcinoma, two had adenocarcinoma in situ, one had mixed adenocarcinoma and small cell carcinoma, one had SCC and small cell carcinoma, one had NSCLC not otherwise specified, one had mucoepidermoid carcinoma, and one had atypical adenomatous hyperplasia. The IGF1R-positive group exhibited significantly higher proportions of patients who were >65 years old, male, had a smoking history, a performance status (PS) ≥1, had SCC, pStage≥2, exhibited pleural invasion, had vascular invasion, or showed PD-L1 expression (all p<0.01, p<0.01, p<0.01, p<0.01, p<0.01, p<0.01, p=0.02, p<0.01, p<0.01, respectively) (Table 1). Multivariable analysis revealed that PD-L1 expression is associated with IGF1R expression (Table 2). Both

142	IGF1R-positive and PD-L1-positive group had a significantly higher smoking index
143	(p<0.01) (Fig. 2A and 2 B), and the IGF1R-positive group had a significantly larger
144	maximum tumor diameter (p<0.01) (Fig. 2C).
145	Fig 1. Immunostaining for IGF1R and PD-L1.
145 146	Fig 1. Immunostaining for IGF1R and PD-L1. (A) Immunostaining for IGF1R reveals predominant cytoplasmic staining. (B)

148

Table 1. Patient characteristics.

	No. of all patients	IGF1R positive	IGF1R negative	
	n=782	n=279 (35.8%)	n= 503 (64.2%)	p-value
Age				
<65	200 (25.6%)	50 (17.9%)	150 (29.8%)	< 0.01
≥65	582 (74.4%)	229 (82.1%)	353 (70.2%)	
Sex				
Male	497 (63.6%)	210 (75.3%)	287 (57.1%)	< 0.01
Female	285 (36.4%)	69 (24.7%)	216 (42.9%)	
Smoking history				
Current/Former	587 (75.1%)	243 (87.1%)	344 (68.4%)	<0.01
Never	195 (24.9%)	36 (12.9%)	159 (31.6%)	
ECOG PS				
0	573 (73.3%)	193 (68.8%)	380 (75.4%)	<0.01
1-3	115 (14.7%)	56 (20.2%)	59 (11.7%)	
Histology				
Sq	218 (27.9%)	137 (49.1%)	81 (16.1%)	<0.01
Non Sq	564 (72.1%)	142 (50.9%)	422 (83.9%)	
pStage				
0-1	494 (63.2%)	137 (49.1%)	357 (71.0%)	< 0.01
2-3	288 (36.8%)	142 (50.9%)	146 (29.0%)	
Adjuvant therapy				
Done	192 (24.6%)	72 (25.8%)	120 (23.9%)	0.55
None	590 (75.4%)	207 (74.2%)	383 (76.1%)	
Pleural invasion				

	Positive	228 (29.2%)	96 (34.4%)	132 (26.2%)	0.02
	Negative	548 (70.1%)	181 (64.9%)	367 (73.0%)	
Lymphatic invasi	on				
	Positive	212 (27.1%)	78 (28.0%)	134 (26.6%)	0.74
	Negative	566 (72.4%)	200 (71.7%)	366 (72.8%)	
Vascular invasion	1				
	Positive	169 (21.6%)	98 (35.1%)	71 (14.1%)	<0.01

180 (64.5%)

68 (24.4%)

211 (75.6%)

429 (85.3%)

32 (6.4%)

471 (93.6%)

149 IGF1R, insulin-like growth factor 1 receptor; ECOG PS, Eastern Cooperative Oncology 150 Group Performance Status; Sq, squamous cell carcinoma; PD-L1, programmed death

609 (77.9%)

100 (12.8%)

682 (87.2%)

151 ligand 1.

152

153

154

155

PD-L1

Table 2. Multivariate analysis of the relationship between IGF1R expression and

PD-L1 expression.

Factor	Reference	OR (95%CI)	p-value
PD-L1	Negative	3.35 (1.95-5.73)	<0.01

IGF1R, insulin-like growth factor 1 receptor; OR, odds ratio; CI, confidence intervals;

PD-L1, programmed death ligand 1.

Negative

Positive

Negative

12/26

< 0.01

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

Fig 2. The association between IGF1R or PD-L1 and smoking index, as well as the correlation between IGF1R and tumor size. (A) Comparison of smoking index between the IGF1R-positive and negative groups. The IGF1R-positive group had a significantly larger smoking index. (B) Comparison of smoking index between PD-L1-positive and negative groups. The PD-L1-positive group had a significantly larger smoking index. (C) Comparison of maximum tumor diameter between IGF1R-positive and negative groups. The IGF1R-positive group had a significantly larger maximum tumor diameter. Relationship between IGF1R and relapse-free survival or overall survival In all patients, IGF1R positivity was associated with worse RFS (p<0.01) and OS (p<0.01) (Fig. 3A and 3B). When evaluated by stage, IGF1R positivity was associated with worse RFS (p<0.01) and OS (p<0.01) in Stage 0-1 (Fig. 4A and 4B). However, no significant differences in RFS or OS were observed between IGF1Rpositive and negative patients in Stage 2 (p=0.60 and p=0.80, respectively) (Fig. 5A and 5B) or Stage 3 (p=0.89 and p=0.15, respectively) (Fig. 6A and 6B). In univariable analysis of RFS in stage 0-1 patients, IGF1R positivity, male, smoking history, ECOG PS >1, pStage 2-3, pleural invasion, lymphatic invasion, and vascular invasion were all

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

associated with significantly worse PFS (Table 3). In the multivariable analysis of RFS in stage 0-1 patients, smoking history, ECOG PS\ge 1, lymphatic invasion, and vascular invasion were associated with significantly worse PFS (Table 3). In univariable analysis of OS in stage 0-1 patients, IGF1R positivity, male, smoking history, ECOG PS\ge 1, SCC and vascular invasion were all associated with significantly worse OS (Table 4). In the multivariable analysis of OS in stage 0-1 patients, ECOG PS≥1 was associated with significantly worse OS (Table 4). Fig 3. Kaplan-Meier curve depicting RFS and OS for all patients. (A) Kaplan-Meier curve depicting RFS for all patients. The IGF1R-positive group exhibited significantly worse RFS. (B) Kaplan-Meier curve depicting OS for all patients. The IGF1R-positive group exhibited significantly worse OS. Fig 4. Kaplan-Meier curve depicting RFS and OS in stage 0-1 patients. (A) Kaplan-Meier curve depicting RFS in stage 0-1 patients. The IGF1R-positive group exhibited significantly worse RFS. (B) Kaplan-Meier curve depicting OS in stage 0-1 patients. The IGF1R-positive group exhibited significantly worse OS. Fig 5. Kaplan-Meier curve depicting RFS and OS in stage 2 patients. (A) Kaplan-Meier curve depicting RFS in stage 2 patients. No significant difference was observed between the IGF1R-positive and negative groups. (B) Kaplan-Meier curve for

15/26

OS in stage 2 patients. No significant difference was observed between the IGF1Rpositive and negative groups.

Fig 6. Kaplan-Meier curve depicting RFS and OS in stage 3 patients.

194

195

196

197

198

199

(A) Kaplan-Meier curve depicting RFS in stage 3 patients. No significant difference in RFS was observed between the IGF1R-positive and negative groups. (B) Kaplan-Meier curve depicting OS in stage 3 patients. No significant difference was observed between the IGF1-positive and negative groups.

Table 3. Multivariable analysis of RFS in stage 0-1 patients.

		RFS of stage 0-1 patients (n=494)						
Factor	Reference	Univariable analysis			Multivariable analysis			
		HR	95%CI	p-value	HR	95%CI	p-value	
IGF1R	Negative	1.71	1.23-2.40	<0.01	1.29	0.85-1.96	0.23	
Age	≤64	1.34	0.91-1.95	0.14				
Sex	Female	2.05	1.45-2.89	< 0.01	1.35	0.87-2.11	0.18	
Smoking history	Never	2.41	1.62-3.58	< 0.01	1.75	1.04-2.95	0.04	
ECOG PS	0	2.13	1.37-3.30	< 0.01	2.05	1.30-3.23	< 0.01	
Histology	NonSq	1.52	1.05-2.21	0.03	0.73	0.45-1.18	0.20	
Adjuvant therapy	Done	0.66	0.66-1.68	0.84				
Pleural invasion	Negative	1.93	1.35-2.76	< 0.01	1.32	0.87-2.04	0.19	

Nagamine H. e	t al.
---------------	-------

Lymphatic invasion	Negative	2.26	1.57-3.25	< 0.01	1.70	1.10-2.63	0.02
Vascular invasion	Negative	2.68	1.80-3.98	<0.01	1.91	1.17-3.12	< 0.01
PD-L1	Negative	1.49	0.90-2.47	0.12			

²⁰⁰ RFS, relapse-free survival; HR, hazard ratio; CI, confidence intervals; IGF1R, insulin-201 like growth factor 1 receptor; ECOG PS, Eastern Cooperative Oncology Group

202 Performance Status; Sq, squamous cell carcinoma; PD-L1, programmed death ligand 1.

Table 4. Multivariable analysis of OS in stage 0-1 patients.

203

		OS of stage 0-1 patients (n=494)					
Factor	Reference	Univariable analysis			Multivariable analysis		
	-	HR	95%CI	p-value	HR	95%CI	p-value
IGF1R	Negative	1.98	1.35-2.91	<0.01	1.40	0.86-2.29	0.17
Age	≤64	1.26	0.81-1.94	0.31			
Sex	Female	2.79	1.82-4.29	< 0.01	1.69	0.99-2.91	0.06
Smoking history	Never	2.81	1.73-4.57	< 0.01	1.70	0.90-3.21	0.10
ECOG PS	0	2.61	1.60-4.28	< 0.01	2.24	1.34-3.73	< 0.01
Histology	NonSq	2.10	1.39-3.16	< 0.01	0.95	0.55-1.64	0.86
Adjuvant therapy	Done	1.14	0.65-1.99	0.65			
Pleural invasion	Negative	1.34	0.86-2.09	0.20			
Lymphatic invasion	Negative	1.39	0.86-2.23	0.18			
Vascular invasion	Negative	2.19	1.36-3.53	< 0.01	1.52	0.85-2.70	0.15

agan		

PD-L	L1 Negative 1.71 0.98-3.01 0.06	
204	OS, overall survival; HR, hazard ratio; CI, confidence intervals; IGF1R, insulin-like	
205	growth factor 1 receptor; ECOG PS, Eastern Cooperative Oncology Group Performance	;
206	Status; Sq, squamous cell carcinoma; PD-L1, programmed death ligand 1.	

Discussion

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

Although previous reports have not consistently linked IGF1R expression to postoperative recurrence or prognosis in lung cancer [11-14], our large-scale, long-term observational study demonstrates that IGF1R expression is associated with worse RFS and OS, particularly in the early stages. In addition, in this study, IGF1R expression was significantly correlated with PD-L1 expression, smoking history, and tumor size. The IGF1R-positive group also showed significantly larger tumor sizes. IGF1R is a factor associated with tumor growth [4], consistent with a relationship between IGF1R expression and tumor size. In addition, IGF1R expression was associated with shorter RFS and OS, particularly in early-stage lung cancer. Many treatment strategies using ICI for neoadjuvant and adjuvant chemotherapy have been developed in recent years [18, 19]. However, due to the favorable prognosis of early-stage lung cancer, it was less amenable to the benefits of neoadjuvant and adjuvant chemotherapy. Based on our study findings, IGF1R expression may serve as an informative marker for determining appropriate perioperative chemotherapy for patients with early-stage lung cancer. Furthermore, despite promising preclinical indications, IGF1R inhibitors have not proven consistently effective in various types of cancer in clinical trials [20-22]. However, recent mouse experiments have revealed that reduced IGF1R expression

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

enhances the effects of ICI [23], and that IGF1R expression correlates with the tumor microenvironment [24], including immune cells. Combining IGF1R inhibitors with ICI may hold promise for future therapies, especially as perioperative treatment for earlystage lung cancer. In this study, we observed a positive correlation between the expression of IGF1R and PD-L1. Notably, in head and neck squamous cell carcinoma, where smoking poses a risk [25], Interleukin-6 (IL-6) has been reported to upregulate IGF1R and PD-L1 expression [16]. In the present study, the IGF1R-positive group had a significantly higher smoking index, consistent with previous studies linking IGF1R expression to smoking [14]. Smoking induces IL-6 expression in the lungs [26], potentially contributing to the upregulation of both IGF1R and PD-L1 expression in lung cancer. Additionally, the IGF1R-positive group had a significantly higher proportion of SCC, widely known to be associated with smoking [17]. Smoking-induced inflammation also enhances COX2 expression, which is associated with IGF1R expression in lung cancer [10]. Various smoking-related mechanisms, such as IL-6 and COX-2, may elucidate the association between IGF1R expression, smoking, SCC, and PD-L1 expression. However, further research is needed to elucidate the mechanism of co-expression of IGF1R and PD-L1. Our unpublished data indicate that OMUL-1, a human squamous

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

lung cancer cell line, expresses high levels of both IGF1R and PD-L1. This cell line may be useful for analyzing the mechanisms responsible for the co-expression of IGF1R and PD-L1. IGF1R expression was correlated with various factors, such as PD-L1, sex, and age, which differed between the IGF1R-positive and negative groups. Additionally, IGF1R expression was positively correlated with smoking index. Given the high prevalence of male smokers in Japan [27], the prevalence of IGF1R-positive lung cancer may be higher in males. Moreover, the smoking index tends to be higher in older patients, and the population of nonsmokers has decreased in recent years [27], which may explain the large number of older adults in the IGF1R-positive group. One limitation of this study stems from its retrospective design. Further research and prospective study are necessary to fully understand the clinical implications of IGF1R expression. In conclusion, our study reveals that higher IGF1R expression correlates with poorer outcomes in terms of RFS and OS, particularly in patients with early-stage lung cancer. Furthermore, our findings indicate a relationship between IGF1R expression in lung cancer and several factors: PD-L1 expression, smoking history, and tumor size.

21/26

Acknowledgment 260 261 We express our gratitude to Akiko Tsuda from the Molecular Oncology and 262 Therapeutics department at Osaka Metropolitan University Graduate School of Medicine for her valuable technical assistance. 263 **Author contributions** 264 Hiroaki Nagamine; conceptualization, data curation, formal analysis, investigation, 265 266 methodology, validation, visualization, writing original draft, writing review and editing 267 Masakazu Yashiro; conceptualization, data curation, formal analysis, investigation, 268 methodology, project administration, supervision, validation, visualization, writing 269 original draft, review and editing, 270 Megumi Mizutani; data curation, formal analysis, investigation, validation, review and editing 271 272 Akira Sugimoto; data curation, formal analysis, investigation, validation, review and 273 editing 274 Yoshiya Matsumoto; methodology, review and editing 275 Yoko Tani; review and editing 276 Kenji Sawa; methodology, review and editing

Hiroyasu Kaneda; methodology, review and editing

277

278 Kazuhiro Yamada; methodology, validation, supervision, review and editing 279 Tetsuya Watanabe; supervision, review and editing Kazuhisa Asai; supervision, review and editing 280 281 Satoshi Suzuki; data curation, formal analysis, investigation, validation, review and 282 editing 283 Tomoya Kawaguchi; review and editing **Competing interests** 284 285 The authors declare no competing interests. **Ethics declarations** 286 287 This study was approved by the Osaka City university Ethics Committee (reference 288 number 2019-006). Informed consent was obtained from the patient. This study has been conducted according to the principles of the declaration of Helsinki. 289

References

290

291

- 292 Wu J, Yu E. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer
- 293 therapy. Cancer Metastasis Rev. 2014;33(2-3):607-17. doi: 10.1007/s10555-013-9482-0.
- 294 PubMed PMID: 24414227: PubMed Central PMCID: PMCPMC4096322.
- 295 2. Motallebnezhad M, Aghebati-Maleki L, Jadidi-Niaragh F, Nickho H, Samadi-Kafil H,
- 296 Shamsasenjan K, et al. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology
- 297 and treatment strategies. Tumour Biol. 2016;37(9):11711-21. Epub 20160721. doi:
- 298 10.1007/s13277-016-5176-x. PubMed PMID: 27444280.
- 299 Hu L, Xu X, Li Q, Chen X, Yuan X, Qiu S, et al. Caveolin-1 increases glycolysis in
- 300 pancreatic cancer cells and triggers cachectic states. Faseb j. 2021;35(8):e21826. doi:
- 301 10.1096/fj.202100121RRR. PubMed PMID: 34320244.
- 302 Heidegger I, Kern J, Ofer P, Klocker H, Massoner P. Oncogenic functions of IGF1R and 4.
- 303 INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis.
- 304 Oncotarget. 2014;5(9):2723-35. doi: 10.18632/oncotarget.1884. PubMed PMID: 24809298;
- 305 PubMed Central PMCID: PMCPMC4058040.
- 306 5. Xu XL, Guo AX, Pan QY, Chang AL, Zhao CR. MiR-99a suppresses cell migration and
- 307 invasion by regulating IGF1R in gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(17):7375-
- 308 82. doi: 10.26355/eurrev 201909 18845. PubMed PMID: 31539124.
- 309 Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Canalejo M, Gotera C, Sola JJ, et al.
- 310 IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung
- 311 metastasis implantation and progression. Oncogene. 2022;41(28):3625-39. Epub 20220610. doi:
- 312 10.1038/s41388-022-02376-w. PubMed PMID: 35688943; PubMed Central PMCID:
- 313 PMCPMC9184253.
- 314 Joehlin-Price AS, Stephens JA, Zhang J, Backes FJ, Cohn DE, Suarez AA. Endometrial
- 315 Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass
- 316 Index and Is Associated with Pathologic Extent and Prognosis. Cancer Epidemiol Biomarkers Prev.
- 317 2016;25(3):438-45. Epub 20151218. doi: 10.1158/1055-9965.Epi-15-1145. PubMed PMID:
- 318 26682991; PubMed Central PMCID: PMCPMC5075967.
- 319 Du P, Liu F, Liu Y, Shao M, Li X, Qin G. Linc00210 enhances the malignancy of thyroid
- 320 cancer cells by modulating miR-195-5p/IGF1R/Akt axis. J Cell Physiol. 2020;235(2):1001-12.
- 321 Epub 20190625. doi: 10.1002/jcp.29016. PubMed PMID: 31240707.
- 322 Xu X, Qiu Y, Chen S, Wang S, Yang R, Liu B, et al. Different Roles of the Insulin-like 9.
- 323 Growth Factor (IGF) Axis in Non-small Cell Lung Cancer. Curr Pharm Des. 2022;28(25):2052-

- 24/26
- 324 64. doi: 10.2174/1381612828666220608122934. PubMed PMID: 36062855.
- 325 Põld M, Krysan K, Põld A, Dohadwala M, Heuze-Vourc'h N, Mao JT, et al.
- 326 Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.
- 327 Cancer Res. 2004;64(18):6549-55. doi: 10.1158/0008-5472.Can-04-1225. PubMed PMID:
- 328 15374967.
- 329 11. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska
- 330 A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival
- 331 in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ
- 332 hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010;28(13):2174-80.
- 333 Epub 20100329. doi: 10.1200/jco.2009.24.6611. PubMed PMID: 20351332; PubMed Central
- 334 PMCID: PMCPMC2860435.
- 335 Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, et al. High coexpression
- 336 of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung
- 337 cancer. Clin Lung Cancer. 2014;15(1):58-66. Epub 20131107. doi: 10.1016/j.cllc.2013.08.005.
- 338 PubMed PMID: 24210543.
- 339 13. Nakagawa M, Uramoto H, Oka S, Chikaishi Y, Iwanami T, Shimokawa H, et al. Clinical
- significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 340
- 341 2012;13(2):136-42. Epub 20111201. doi: 10.1016/j.cllc.2011.10.006. PubMed PMID: 22133293.
- 342 14. Zhao S, Qiu Z, He J, Li L, Li W. Insulin-like growth factor receptor 1 (IGF1R) expression
- 343 and survival in non-small cell lung cancer patients: a meta-analysis. Int J Clin Exp Pathol.
- 344 2014;7(10):6694-704. Epub 20140915. PubMed PMID: 25400749; PubMed Central PMCID:
- 345 PMCPMC4230063.
- 346 Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. J 15.
- 347 Thorac Oncol. 2016;11(7):964-75. Epub 20160423. doi: 10.1016/j.jtho.2016.04.014. PubMed
- 348 PMID: 27117833; PubMed Central PMCID: PMCPMC5353357.
- 349 Li J, Xiao Y, Yu H, Jin X, Fan S, Liu W. Mutual connected IL-6, EGFR and LIN28/Let7-
- 350 related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy.
- Front Oncol. 2023;13:1140133. Epub 20230412. doi: 10.3389/fonc.2023.1140133. PubMed 351
- 352 PMID: 37124491; PubMed Central PMCID: PMCPMC10130400.
- 353 17. Wang X, Wang T, Hua J, Cai M, Qian Z, Wang C, et al. Histological types of lung cancer
- 354 attributable to fine particulate, smoking, and genetic susceptibility. Sci Total Environ.
- 355 2023;858(Pt 2):159890. Epub 20221102. doi: 10.1016/j.scitotenv.2022.159890. PubMed PMID:
- 356 36334679.
- 357 Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant 18.
- 358 Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-85.
- 359 Epub 20220411. doi: 10.1056/NEJMoa2202170. PubMed PMID: 35403841; PubMed Central

- 360 PMCID: PMCPMC9844511.
- 361 Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant
- 362 atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer
- randomised, 363 multicentre, (IMpower010): open-label, phase trial.
- 364 2021;398(10308):1344-57. Epub 20210920. doi: 10.1016/s0140-6736(21)02098-5. PubMed
- 365 PMID: 34555333.
- 366 20. Qu X, Wu Z, Dong W, Zhang T, Wang L, Pang Z, et al. Update of IGF-1 receptor
- 367 inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on
- 368 cancer therapy. Oncotarget. 2017;8(17):29501-18. doi: 10.18632/oncotarget.15704. PubMed
- 369 PMID: 28427155; PubMed Central PMCID: PMCPMC5438747.
- 370 21. Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, et al. A
- 371 Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed
- 372 Cancer. Oncologist. 2016;21(10):1163-4. Epub 20160930. Small-Cell Lung
- 10.1634/theoncologist.2016-0220. PubMed PMID: 27694157; PubMed Central PMCID: 373
- 374 PMCPMC5061534.
- 375 22. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-
- 376 906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a
- 377 double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426-35. Epub 20150318. doi:
- 378 10.1016/s1470-2045(15)70081-1. PubMed PMID: 25795408.
- 379 23. Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, et al. Short-term
- 380 starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade.
- 381 Nat Cancer. 2020;1(1):75-85. Epub 20200113. doi: 10.1038/s43018-019-0007-9. PubMed
- 382 PMID: 35121837.
- 383 24. Galifi CA, Wood TL. Insulin-like growth factor-1 receptor crosstalk with integrins,
- 384 cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in
- 385 cancer. Endocr Relat Cancer. 2023;30(10). Epub 20230825. doi: 10.1530/erc-23-0031. PubMed
- 386 PMID: 37490874.
- 387 25. Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, et al. Association of Oral Microbiome
- 388 With Risk for Incident Head and Neck Squamous Cell Cancer. JAMA Oncol. 2018;4(3):358-65.
- 389 doi: 10.1001/jamaoncol.2017.4777. PubMed PMID: 29327043; PubMed Central PMCID:
- 390 PMCPMC5885828.
- 391 Francus T, Romano PM, Manzo G, Fonacier L, Arango N, Szabo P. IL-1, IL-6, and 26.
- 392 PDGF mRNA expression in alveolar cells following stimulation with a tobacco-derived antigen.
- 393 Cell Immunol. 1992;145(1):156-74. doi: 10.1016/0008-8749(92)90320-o. PubMed PMID:
- 394 1423641.
- 395 27. Tanaka H, Mackenbach JP, Kobayashi Y. Widening Socioeconomic Inequalities in

396 Smoking in Japan, 2001-2016. J Epidemiol. 2021;31(6):369-77. Epub 20201125. doi: 397 10.2188/jea.JE20200025. PubMed PMID: 32595181; PubMed Central PMCID:

398 PMCPMC8126678.

399

Figure 1. Nagamine H. et al.




Figure1

Figure 2. Nagamine H. et al.




Figure2

Figure 3. Nagamine H. et al.




Figure3

Figure 4. Nagamine H. et al.




Figure4

Figure 5. Nagamine H. et al.




Figure5

Figure 6. Nagamine H. et al.




Figure6